Glenmark Pharma Set to Launch Ropivacaine Hydrochloride Injection in the USA, Expanding Injectable Portfolio

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, is poised to launch Ropivacaine Hydrochloride Injection USP by November 2025. This move represents a significant expansion of Glenmark’s injectable product portfolio in the competitive US pharmaceutical market.

Ropivacaine is a local anesthetic widely used for surgery and short-term pain management. Glenmark’s product will be offered in three single-dose vial strengths: 40 mg/20 mL, 150 mg/30 mL, and 200 mg/20 mL. The injectable formulation is bioequivalent and therapeutically equivalent to the reference drug Naropin®, marketed by Fresenius Kabi USA, LLC, which posted approximately $20.9 million in annual sales for the 12-month period ending August 2025, according to IQVIA® sales data.

Marc Kikuchi, President and Business Head, North America for Glenmark, expressed enthusiasm about the launch, emphasizing the company’s commitment to providing high-quality yet affordable alternatives for patients in need. The expansion aligns with Glenmark’s strategic goal of strengthening its position in specialty injectables and diversifying its product offerings.

This launch follows Glenmark’s recent expansion in the US pharmaceutical space, including oncology and anti-infectives, leveraging its global manufacturing footprint spanning four continents with 11 world-class facilities. Glenmark’s dedication to innovation and sustainability further distinguishes it as a key player in the global pharma landscape.

Notable Updates:

Launch planned for November 2025 with three dosage strengths (40 mg/20 mL, 150 mg/30 mL, 200 mg/20 mL) in single-dose vials.

Product is bioequivalent to Naropin®, a market leader with $20.9 million annual sales.

The launch broadens Glenmark’s injectable portfolio in the US specialty pharmaceutical market.

Glenmark operates 11 manufacturing sites across four continents and serves over 80 countries worldwide.

Leadership highlights strategic focus on quality, affordability, and expanding therapeutic coverage.

Glenmark recently achieved approval for emission reduction targets, underscoring sustainable business practices.

Major Takeaway:
Glenmark’s introduction of Ropivacaine Hydrochloride Injection positions the company competitively within the US injectable market, addressing critical therapeutic needs while reinforcing its commitment to affordable, high-quality pharmaceuticals and global growth.

Sources: Glenmark Pharmaceuticals official release, Reuters, Business Upturn, IQVIA data, NSE India